Stellar Biotechnologies launches keyhole limpet hemocyanin ELISA
30 April 2012
Stellar Biotechnologies, Inc. has launched the Stellar KLH
ELISA test kits for the rapid, quantitative measure of anti-KLH
antibodies in serum or plasma samples.
Stellar has launched six different kits to measure either IgG or IgM
antibodies in a range of preclinical models. The new assay kits are
the first anti-KLH ELISA's (enzyme-linked immunosorbent assays) made
with the Company's proprietary Stellar KLH Protein. This provides
the unique benefits of quantitative measurements with wide dynamic
range, low assay background and reproducible linearity.
"We saw that the quality of KLH used to make anti-KLH ELISA's can
affect test results," said Frank Oakes, CEO and President of Stellar
Biotechnologies. "Our goal was to apply Stellar KLH technology to
improve the predictive value of pharmaceutical immunotoxicology
testing using higher quality, standardized products — both KLH
protein and assays — not available to researchers before."
In pharmaceutical research settings, KLH protein is often used as
a test agent to determine a candidate drug's effects on the immune
system. The tests are particularly relevant to new classes of immune
modulating drugs in development. KLH can be used to assess both
humoral and cellular immune responses. The Stellar KLH ELISA
measures anti-KLH antibody levels following KLH immune stimulation.
Stellar KLH ELISA Test Kits, together with Stellar KLH Protein
test agent, are intended to provide high level of control and
consistency in immune response testing. Stellar's product line
targets the increasing need among clinical researchers and
pharmaceutical developers for improved assay sensitivity and